142 related articles for article (PubMed ID: 38123705)
1. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
Grosser B; Emmerson J; Reitsam NG; Cunningham D; Nankivell M; Langley RE; Allum WH; Trepel M; Märkl B; Grabsch HI
Br J Cancer; 2024 Feb; 130(3):457-466. PubMed ID: 38123705
[TBL] [Abstract][Full Text] [Related]
2. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes.
Grosser B; Glückstein MI; Dhillon C; Schiele S; Dintner S; VanSchoiack A; Kroeppler D; Martin B; Probst A; Vlasenko D; Schenkirsch G; Märkl B
J Pathol; 2022 Jan; 256(1):71-82. PubMed ID: 34580877
[TBL] [Abstract][Full Text] [Related]
3. Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response.
Grosser B; Heyer CM; Austgen J; Sipos E; Reitsam NG; Hauser A; VanSchoiack A; Kroeppler D; Vlasenko D; Probst A; Novotny A; Weichert W; Keller G; Schlesner M; Märkl B
Gastric Cancer; 2024 Jan; 27(1):72-85. PubMed ID: 37874427
[TBL] [Abstract][Full Text] [Related]
4. Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.
Reitsam NG; Grosser B; Enke JS; Mueller W; Westwood A; West NP; Quirke P; Märkl B; Grabsch HI
Transl Oncol; 2024 Jun; 44():101913. PubMed ID: 38593584
[TBL] [Abstract][Full Text] [Related]
5. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.
Ulase D; Behrens HM; Röcken C
Virchows Arch; 2024 May; ():. PubMed ID: 38748262
[TBL] [Abstract][Full Text] [Related]
6. Stroma AReactive Invasion Front Areas (SARIFA)-A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study.
Martin B; Grosser B; Kempkens L; Miller S; Bauer S; Dhillon C; Banner BM; Brendel EM; Sipos É; Vlasenko D; Schenkirsch G; Schiele S; Müller G; Märkl B
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638364
[TBL] [Abstract][Full Text] [Related]
7. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
[TBL] [Abstract][Full Text] [Related]
8. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham D; Stenning SP; Smyth EC; Okines AF; Allum WH; Rowley S; Stevenson L; Grabsch HI; Alderson D; Crosby T; Griffin SM; Mansoor W; Coxon FY; Falk SJ; Darby S; Sumpter KA; Blazeby JM; Langley RE
Lancet Oncol; 2017 Mar; 18(3):357-370. PubMed ID: 28163000
[TBL] [Abstract][Full Text] [Related]
9. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA).
Reitsam NG; Märkl B; Dintner S; Sipos E; Grochowski P; Grosser B; Sommer F; Eser S; Nerlinger P; Jordan F; Rank A; Löhr P; Waidhauser J
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765951
[TBL] [Abstract][Full Text] [Related]
10. Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology.
Reitsam NG; Grozdanov V; Löffler CML; Muti HS; Grosser B; Kather JN; Märkl B
Cancer Gene Ther; 2024 Feb; 31(2):207-216. PubMed ID: 37990064
[TBL] [Abstract][Full Text] [Related]
11. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
Smyth EC; Nyamundanda G; Cunningham D; Fontana E; Ragulan C; Tan IB; Lin SJ; Wotherspoon A; Nankivell M; Fassan M; Lampis A; Hahne JC; Davies AR; Lagergren J; Gossage JA; Maisey N; Green M; Zylstra JL; Allum WH; Langley RE; Tan P; Valeri N; Sadanandam A
Ann Oncol; 2018 Dec; 29(12):2356-2362. PubMed ID: 30481267
[TBL] [Abstract][Full Text] [Related]
12. Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.
Allum WH; Smyth EC; Blazeby JM; Grabsch HI; Griffin SM; Rowley S; Cafferty FH; Langley RE; Cunningham D
Br J Surg; 2019 Aug; 106(9):1204-1215. PubMed ID: 31268180
[TBL] [Abstract][Full Text] [Related]
13. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N
J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411
[TBL] [Abstract][Full Text] [Related]
14. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.
Okines AF; Thompson LC; Cunningham D; Wotherspoon A; Reis-Filho JS; Langley RE; Waddell TS; Noor D; Eltahir Z; Wong R; Stenning S
Ann Oncol; 2013 May; 24(5):1253-61. PubMed ID: 23233651
[TBL] [Abstract][Full Text] [Related]
15. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
Athauda A; Nankivell M; Langley RE; Alderson D; Allum W; Grabsch HI; Starling N; Chau I; Cunningham D
Eur J Cancer; 2020 Sep; 137():45-56. PubMed ID: 32745964
[TBL] [Abstract][Full Text] [Related]
16. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
Stahl M; Maderer A; Lordick F; Mihaljevic AL; Kanzler S; Hoehler T; Thuss-Patience P; Mönig S; Kunzmann V; Schroll S; Sandermann A; Tannapfel A; Meyer HJ; Schuhmacher C; Wilke H; Moehler M;
Eur J Cancer; 2018 Apr; 93():119-126. PubMed ID: 29501977
[TBL] [Abstract][Full Text] [Related]
17. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
Smyth EC; Wotherspoon A; Peckitt C; Gonzalez D; Hulkki-Wilson S; Eltahir Z; Fassan M; Rugge M; Valeri N; Okines A; Hewish M; Allum W; Stenning S; Nankivell M; Langley R; Cunningham D
JAMA Oncol; 2017 Sep; 3(9):1197-1203. PubMed ID: 28241187
[TBL] [Abstract][Full Text] [Related]
18. Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer.
Karagkounis G; Squires MH; Melis M; Poultsides GA; Worhunsky D; Jin LX; Fields RC; Spolverato G; Pawlik TM; Votanopoulos KI; Levine EA; Schmidt C; Bloomston M; Cho CS; Weber S; Masi A; Berman R; Pachter HL; Staley CA; Newman E; Maithel SK; Hatzaras I
J Gastrointest Surg; 2017 Dec; 21(12):1984-1992. PubMed ID: 28963709
[TBL] [Abstract][Full Text] [Related]
19. Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study.
Hu Q; Wang Y; Yao S; Mao Y; Liu L; Li Z; Chen Y; Zhang S; Li Q; Zhao Y; Fan X; Cui Y; Zhao K; Liu Z
Cancer Res Commun; 2023 Jun; 3(6):1057-1066. PubMed ID: 37377615
[TBL] [Abstract][Full Text] [Related]
20. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
